Shares of medical technology company Integer Holdings (NYSE:ITGR)
jumped 4.2% in the morning session after the company reported better-than-expected fourth-quarter 2025 revenue and earnings, alongside encouraging profit guidance for the upcoming year. The medical device manufacturer's fourth-quarter revenue grew 5% year-over-year to $472.1 million, surpassing Wall Street's estimates. Its adjusted earnings per share (EPS) of $1.76 also beat expectations and marked a 23% increase from the same period in the prior year. Looking ahead, Integer provided an adjusted EPS forecast for 2026 with a midpoint of $6.54, which was 3.8% above analysts' projections. This strong profit outlook likely overshadowed a weaker forecast for flat revenue growth, giving investors reason for optimism.
Medical technology company Integer Holdings (NYSE:ITGR) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $472.1 million. The company expects the full year’s revenue to be around $1.85 billion, close to analysts’ estimates. Its non-GAAP profit of $1.76 per share was 3.6% above analysts’ consensus estimates.
What a brutal six months it’s been for Integer Holdings. The stock has dropped 23.1% and now trades at $85.78, rattling many shareholders. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Integer Holdings Corp (ITGR) is a value stock with strong valuation metrics, solid profitability, and a stable financial position, indicating potential market undervaluation.
Looking back on medical devices & supplies - specialty stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Integer Holdings (NYSE:ITGR) and its peers.
Integer Holdings’ third quarter results were overshadowed by management’s acknowledgment of unexpected headwinds tied to lower-than-anticipated adoption of several new products. CEO-elect Payman Khales explained that multiple customers revised their forecasts downward, impacting both the Cardio & Vascular and Neuromodulation product lines. These customer-driven changes, which management described as “highly unusual,” led to a reduction in the company’s full-year outlook. Khales clarified, “We recently received customer updates related to the adoption of new products in the market that we expect will impact the next 3 quarters.”
Medical technology company Integer Holdings (NYSE:ITGR) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.4% year on year to $467.7 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $1.79 per share was 6.8% above analysts’ consensus estimates.
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares plummeting a staggering 31.4%. The significant sell-off came despite the company reporting strong third-quarter 2025 earnings that largely met or exceeded
Shares of medical technology company Integer Holdings (NYSE:ITGR)
fell 31.4% in the afternoon session after the company reported third quarter earnings which revealed a significant reduction in its full-year profit forecast.
